168 related articles for article (PubMed ID: 38687247)
1. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract][Full Text] [Related]
2. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
[TBL] [Abstract][Full Text] [Related]
3. The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments.
Rayson VC; Harris MA; Savas P; Hun ML; Virassamy B; Salgado R; Loi S
Trends Cancer; 2024 Jun; 10(6):490-506. PubMed ID: 38521654
[TBL] [Abstract][Full Text] [Related]
4. Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.
Li Y; Yue L; Zhang S; Wang X; Zhu YN; Liu J; Ren H; Jiang W; Wang J; Zhang Z; Liu T
Comput Biol Med; 2024 Jun; 176():108537. PubMed ID: 38744008
[TBL] [Abstract][Full Text] [Related]
5. Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma.
Huang X; Anderson SA; Siegal GP; Wei S; Liu S; Yang J; Roisin P; Pickens JT; Huo L; Sahin AA; Granada CP; Chen S
Clin Breast Cancer; 2024 Jun; 24(4):e310-e318. PubMed ID: 38492995
[TBL] [Abstract][Full Text] [Related]
6. IR-780 Dye-based Targeting of Cancer-associated Fibroblasts Improves Cancer Immunotherapy by Increasing Intra-tumoral T Lymphocytes Infiltration.
Yang W; Chen Z; Qu L; Zhang C; Chen H; Zheng J; Chen W; Tan X; Shi C
Curr Cancer Drug Targets; 2024; 24(6):642-653. PubMed ID: 38310462
[TBL] [Abstract][Full Text] [Related]
7. B7-H4 reduces the infiltration of CD8+T cells and induces their anti-tumor dysfunction in gliomas.
Qi Y; Hu L; Ji C; Yang X; Yao J; Chen D; Yao Y
Neoplasia; 2024 Aug; 54():101007. PubMed ID: 38796932
[TBL] [Abstract][Full Text] [Related]
8. Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy.
Sun J; Lu Q; Sanmamed MF; Wang J
Clin Cancer Res; 2021 Feb; 27(3):680-688. PubMed ID: 32958700
[TBL] [Abstract][Full Text] [Related]
9. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
Michaels E; Chen N; Nanda R
Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617
[TBL] [Abstract][Full Text] [Related]
10. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract][Full Text] [Related]
11. RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors.
Ganesh S; Kim MJ; Lee J; Feng X; Ule K; Mahan A; Krishnan HS; Wang Z; Anzahaee MY; Singhal G; Korboukh I; Lockridge JA; Sanftner L; Rijnbrand R; Abrams M; Brown BD
Mol Ther; 2024 Jun; 32(6):1895-1916. PubMed ID: 38549376
[TBL] [Abstract][Full Text] [Related]
12. Evaluating immunotherapeutic outcomes in triple-negative breast cancer with a cholesterol radiotracer in mice.
Ciavattone NG; Guan N; Farfel A; Stauff J; Desmond T; Viglianti BL; Scott PJ; Brooks AF; Luker GD
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38502228
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.
Zhang R; Mao G; Tang Y; Li C; Gao Y; Nie W; Song T; Liu S; Zhang P; Tao K; Li W
Cancer Immunol Immunother; 2024 Jun; 73(8):151. PubMed ID: 38832951
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1.
Ibrahim AA; Fujimura T; Uno T; Terada T; Hirano KI; Hosokawa H; Ohta A; Miyata T; Ando K; Yahata T
Front Immunol; 2024; 15():1365894. PubMed ID: 38779680
[TBL] [Abstract][Full Text] [Related]
15. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape.
Kirthiga Devi SS; Singh S; Joga R; Patil SY; Meghana Devi V; Chetan Dushantrao S; Dwivedi F; Kumar G; Kumar Jindal D; Singh C; Dhamija I; Grover P; Kumar S
Eur J Pharm Biopharm; 2024 Jul; 200():114323. PubMed ID: 38754524
[TBL] [Abstract][Full Text] [Related]
16. Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.
Ho M; Bonavida B
Cells; 2024 May; 13(10):. PubMed ID: 38786085
[TBL] [Abstract][Full Text] [Related]
17. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Lu MM; Yang Y
Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
[TBL] [Abstract][Full Text] [Related]
18. DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers.
Pineda JMB; Bradley RK
Elife; 2024 Jun; 12():. PubMed ID: 38829686
[TBL] [Abstract][Full Text] [Related]
19. The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations.
Santoro A; Angelico G; Inzani F; Arciuolo D; d'Amati A; Addante F; Travaglino A; Scaglione G; D'Alessandris N; Valente M; Tinnirello G; Raffone A; Narducci N; Piermattei A; Cianfrini F; Bragantini E; Zannoni GF
Gynecol Oncol; 2024 May; 184():57-66. PubMed ID: 38295614
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma.
Tatarova Z; Blumberg DC; Bensen A; Mills GB; Jonas O
Cells; 2023 Jan; 12(2):. PubMed ID: 36672243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
